Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
Standard
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. / Reich, Kristian; Conrad, Curdin; Kristensen, Lars Erik; Smith, Saxon D; Puig, Luis; Rich, Phoebe; Sapin, Christophe; Holzkaemper, Thorsten; Koppelhus, Uffe; Schuster, Christopher.
In: J DERMATOL TREAT, Vol. 33, No. 3, 05.2022, p. 1652-1660.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
AU - Reich, Kristian
AU - Conrad, Curdin
AU - Kristensen, Lars Erik
AU - Smith, Saxon D
AU - Puig, Luis
AU - Rich, Phoebe
AU - Sapin, Christophe
AU - Holzkaemper, Thorsten
AU - Koppelhus, Uffe
AU - Schuster, Christopher
PY - 2022/5
Y1 - 2022/5
N2 - BACKGROUND: Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics.OBJECTIVE: To evaluate the comparative efficacy of approved biologics in achieving complete resolution of NP at week 24‒26.METHODS: A network meta-analysis (NMA) was conducted to indirectly compare the efficacy of six biologics in achieving complete resolution of NP at week 24‒26 in patients with moderate-to-severe psoriasis and concomitant NP. Complete resolution of NP was defined as a score of zero on the Nail Psoriasis Severity Index (NAPSI), modified NAPSI (mNAPSI) or Physician's Global Assessment of Fingernails (PGA-F).RESULTS: The probability of achieving complete resolution of NP was highest for ixekizumab (46.5%; 95% credibility interval [CrI] 35.1‒58.0; Surface Under the Cumulative RAnking curve [SUCRA] 97%), followed by brodalumab (37.0%; 17.0‒61.0; 79%), adalimumab (28.3%; 24.4‒32.4; 62%), guselkumab (27.7%; 21.1‒35.1; 58%), ustekinumab (20.8%; 10.2‒35.2; 37%), and infliximab (0.8%; 0.0‒8.9; 17%).CONCLUSION: In patients with moderate-to-severe psoriasis and concomitant NP, ixekizumab has the greatest likelihood among approved biologics of achieving complete resolution of NP at week 24‒26. Findings should be interpreted carefully because of inherent study limitations.
AB - BACKGROUND: Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics.OBJECTIVE: To evaluate the comparative efficacy of approved biologics in achieving complete resolution of NP at week 24‒26.METHODS: A network meta-analysis (NMA) was conducted to indirectly compare the efficacy of six biologics in achieving complete resolution of NP at week 24‒26 in patients with moderate-to-severe psoriasis and concomitant NP. Complete resolution of NP was defined as a score of zero on the Nail Psoriasis Severity Index (NAPSI), modified NAPSI (mNAPSI) or Physician's Global Assessment of Fingernails (PGA-F).RESULTS: The probability of achieving complete resolution of NP was highest for ixekizumab (46.5%; 95% credibility interval [CrI] 35.1‒58.0; Surface Under the Cumulative RAnking curve [SUCRA] 97%), followed by brodalumab (37.0%; 17.0‒61.0; 79%), adalimumab (28.3%; 24.4‒32.4; 62%), guselkumab (27.7%; 21.1‒35.1; 58%), ustekinumab (20.8%; 10.2‒35.2; 37%), and infliximab (0.8%; 0.0‒8.9; 17%).CONCLUSION: In patients with moderate-to-severe psoriasis and concomitant NP, ixekizumab has the greatest likelihood among approved biologics of achieving complete resolution of NP at week 24‒26. Findings should be interpreted carefully because of inherent study limitations.
KW - Biological Products/therapeutic use
KW - Humans
KW - Nail Diseases/drug therapy
KW - Network Meta-Analysis
KW - Psoriasis/drug therapy
KW - Severity of Illness Index
KW - Treatment Outcome
U2 - 10.1080/09546634.2021.1892024
DO - 10.1080/09546634.2021.1892024
M3 - SCORING: Journal article
C2 - 33641593
VL - 33
SP - 1652
EP - 1660
JO - J DERMATOL TREAT
JF - J DERMATOL TREAT
SN - 0954-6634
IS - 3
ER -